1. Home
  2. COOK vs GHRS Comparison

COOK vs GHRS Comparison

Compare COOK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$1.08

Market Cap

141.1M

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$12.61

Market Cap

892.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
GHRS
Founded
1985
2018
Country
United States
Ireland
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.1M
892.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
COOK
GHRS
Price
$1.08
$12.61
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$2.04
$30.11
AVG Volume (30 Days)
924.1K
235.7K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$582,799,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$6.85
52 Week High
$2.70
$20.50

Technical Indicators

Market Signals
Indicator
COOK
GHRS
Relative Strength Index (RSI) 56.94 40.90
Support Level $1.00 $12.04
Resistance Level $1.16 $13.33
Average True Range (ATR) 0.10 0.79
MACD 0.01 -0.13
Stochastic Oscillator 78.37 19.50

Price Performance

Historical Comparison
COOK
GHRS

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: